Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.

Current oncology reports - 4 Nov 2021

Ferrucci Pier Francesco, Lens Marko, Cocorocchio Emilia

Abstract excerpt

PURPOSE OF REVIEW: To review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma. RECENT FINDINGS: Programmed death-1 pathway inhibitors administered with BRAF/MEK inhibitors showed promising anti-tumour activity in BRAF-mutated advanced melanoma and were investigated for safety and efficacy in three large...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Immunologic Factors
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 34735635
DOI: 10.1007/s11912-021-01134-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.PMID 34735635Read ↗

The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?Semantic proximity Read ↗

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.Semantic proximity Read ↗

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.Semantic proximity Read ↗

Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.Semantic proximity Read ↗

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.Semantic proximity Read ↗

Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.Semantic proximity Read ↗

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Semantic proximity Read ↗

Melanoma Treatments: Advances and Mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.